Abstract | BACKGROUND: METHODS: Seventy-four cocaine- and opioid-codependent (DSM-V) subjects were stabilized on methadone for 2 weeks and subsequently randomized into disulfiram (250 mg/day, n = 34) and placebo groups (n = 40) for 10 weeks. We genotyped the DBH gene polymorphism, -1021C/T (rs1611115), that reduces DβH enzyme levels and evaluated its role for increasing cocaine free urines with disulfiram. RESULTS: With repeated measures analysis of variance, corrected for population structure, disulfiram pharmacotherapy reduced cocaine-positive urines from 80% to 62% (p = .0001), and this disulfiram efficacy differed by DBH genotype group. Patients with the normal DβH level genotype dropped from 84% to 56% on disulfiram (p = .0001), whereas those with the low DBH level genotype showed no disulfiram effect. CONCLUSIONS:
|
Authors | Thomas R Kosten, Guiying Wu, Wen Huang, Mark J Harding, Sara C Hamon, Jaakko Lappalainen, David A Nielsen |
Journal | Biological psychiatry
(Biol Psychiatry)
Vol. 73
Issue 3
Pg. 219-24
(Feb 01 2013)
ISSN: 1873-2402 [Electronic] United States |
PMID | 22906516
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Copyright | Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Dopamine beta-Hydroxylase
- Disulfiram
- Methadone
|
Topics |
- Adult
- Cocaine-Related Disorders
(complications, drug therapy, genetics)
- Disulfiram
(therapeutic use)
- Dopamine beta-Hydroxylase
(genetics)
- Drug Therapy, Combination
- Female
- Genotype
- Humans
- Male
- Methadone
(therapeutic use)
- Middle Aged
- Opioid-Related Disorders
(complications, drug therapy, genetics)
- Polymorphism, Single Nucleotide
- Treatment Outcome
|